Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sichuan Huiyu Pharmaceutical Co (SHSE:688553) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sichuan Huiyu Pharmaceutical Co EBITDA Margin % Related Terms
Sichuan Huiyu Pharmaceutical Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Huiyu Pharmaceutical Co EBITDA Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sichuan Huiyu Pharmaceutical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sichuan Huiyu Pharmaceutical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sichuan Huiyu Pharmaceutical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sichuan Huiyu Pharmaceutical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Huiyu Pharmaceutical Co (SHSE:688553) has a EBITDA Margin % of 7.38% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sichuan Huiyu Pharmaceutical Co and its competitors. This is 66% below median its historical median of 21.87. According to the industry distribution chart, Sichuan Huiyu Pharmaceutical Co ranks #719 out of 960 companies in the Drug Manufacturers industry, placing it in the top 74.9%.
Is Sichuan Huiyu Pharmaceutical Co's EBITDA Margin % too high?
Sichuan Huiyu Pharmaceutical Co's current EBITDA Margin % of 7.38% is 66% below median its 10-year median of 21.87. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Sichuan Huiyu Pharmaceutical Co's value of 7.38% is 40.8% below this industry median. Based on the distribution chart, Sichuan Huiyu Pharmaceutical Co ranks #719 out of 960 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sichuan Huiyu Pharmaceutical Co has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Huiyu Pharmaceutical Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sichuan Huiyu Pharmaceutical Co ranks #719 out of 960 companies for EBITDA Margin %. This places Sichuan Huiyu Pharmaceutical Co in the lower half of its industry. The industry median EBITDA Margin % is 12.47. Sichuan Huiyu Pharmaceutical Co's value of 7.38% is 40.8% below this benchmark. While the company's 10-year median is 21.87 vs. the industry median of 12.47, Sichuan Huiyu Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sichuan Huiyu Pharmaceutical Co's current EBITDA Margin % of 7.38% is 40.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sichuan Huiyu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sichuan Huiyu Pharmaceutical Co's current EBITDA Margin % is 7.38%, which is 66% below median its own 10-year median of 21.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Huiyu Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Huiyu Pharmaceutical Co (SHSE:688553) is currently considered Fairly Valued. The stock's GF Value™ is ¥9.85, compared to a current price of ¥10.27 — trading 4.3% above its estimated fair value. The current EBITDA Margin % is 7.38%, which is 66% below median its 10-year median of 21.87 and 40.8% below the Drug Manufacturers industry median of 12.47. Sichuan Huiyu Pharmaceutical Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sichuan Huiyu Pharmaceutical Co (SHSE:688553), the current EBITDA Margin % is 7.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sichuan Huiyu Pharmaceutical Co (SHSE:688553) Overvalued in 2026?
Based on GuruFocus' analysis, Sichuan Huiyu Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥10.27 is trading 4.3% above its estimated GF Value™ of ¥9.85.
GuruFocus considers Sichuan Huiyu Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:688553:
EBITDA Margin %: 7.38% (66% below median its 10-year median of 21.87)
GF Value™: ¥9.85 vs. price of ¥10.27 (4.3% above fair value)
Industry Position: 40.8% below the Drug Manufacturers median (#719 of 960)
No single metric tells the full story. See the SHSE:688553 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sichuan Huiyu Pharmaceutical Co Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688553 has been successfully added to your 
